About Testicular acid phosphatase
Testicular acid phosphatase (ACP4) is a protein
from Homo sapiens identified by UniProt accession
Q9BZG2, 426 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Testicular acid phosphatase |
| UniProt accession | Q9BZG2 |
| Gene | ACP4 |
| Organism | Homo sapiens |
| Length | 426 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (61)
Diseases linked to this target (Open Targets).
- Hypoplastic amelogenesis imperfecta · score 0.75
- amelogenesis imperfecta, type ij · score 0.73
- amelogenesis imperfecta · score 0.17
- Hypomaturation amelogenesis imperfecta · score 0.11
- cystatin C measurement · score 0.08
- amelogenesis imperfecta type 3B · score 0.07
- amelogenesis imperfecta, IIa 1K · score 0.07
- amelogenesis imperfecta hypomaturation type 2A4 · score 0.07
- dentin dysplasia type II · score 0.07
- dentinogenesis imperfecta type 3 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9BZG2-F1 | alphafold | PREDICTED | 87.61 | — |
Amino-acid sequence (426 residues)
MAGLGFWGHP AGPLLLLLLL VLPPRALPEG PLVFVALVFR HGDRAPLASY PMDPHKEVAS TLWPRGLGQL TTEGVRQQLE LGRFLRSRYE AFLSPEYRRE EVYIRSTDFD RTLESAQANL AGLFPEAAPG SPEARWRPIP VHTVPVAEDK LLRFPMRSCP RYHELLREAT EAAEYQEALE GWTGFLSRLE NFTGLSLVGE PLRRAWKVLD TLMCQQAHGL PLPAWASPDV LRTLAQISAL DIGAHVGPPR AAEKAQLTGG ILLNAILANF SRVQRLGLPL KMVMYSAHDS TLLALQGALG LYDGHTPPYA ACLGFEFRKH LGNPAKDGGN VTVSLFYRND SAHLPLPLSL PGCPAPCPLG RFYQLTAPAR PPAHGVSCHG PYEAAIPPAP VVPLLAGAVA VLVALSLGLG LLAWRPGCLR ALGGPV
Explore Testicular acid phosphatase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets